Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.
Amarasinghe, K.K., Evdokimov, A.G., Xu, K., Clark, C.M., Maier, M.B., Srivastava, A., Colson, A.O., Gerwe, G.S., Stake, G.E., Howard, B.W., Pokross, M.E., Gray, J.L., Peters, K.G.(2006) Bioorg Med Chem Lett 16: 4252-4256
- PubMed: 16759857 
- DOI: https://doi.org/10.1016/j.bmcl.2006.05.074
- Primary Citation of Related Structures:  
2H02, 2H03, 2H04 - PubMed Abstract: 
The sulfamic acid phosphotyrosine mimetic was coupled with a previously known malonate template to obtain highly selective and potent inhibitors of HPTPbeta. Potentially hydrolyzable malonate ester functionalities were replaced with 1,2,4-oxadiazoles without a significant effect on HPTPbeta potency.
Organizational Affiliation: 
Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA. Amarasinghe.kk@pg.com